Form 4: DURECT Director Reports Merger-Related Stock Changes

A DURECT Corporation director reported changes in beneficial ownership following the company's merger with a Bausch Health Americas subsidiary.

Summary

• Judith J. Robertson, a Director of DURECT Corporation, reported changes in her beneficial ownership of company securities.
• The changes are a direct result of the merger agreement dated July 28, 2025, where Bausch Health Americas, Inc. (Parent) acquired DURECT.
• A tender offer was completed by BHC Lyon Merger Sub, Inc. (Purchaser), a subsidiary of Parent, for DURECT's Common Stock.
• Tendering stockholders received $1.75 per share in cash, plus one non-tradeable contingent value right (CVR) per share.
• The CVR represents a contractual right to receive a pro rata portion of two milestone payments, totaling up to $350,000,000 in aggregate, contingent on achievement of specified milestones.
• The merger became effective on September 11, 2025, with DURECT continuing as a wholly-owned subsidiary of Parent.
• Ms. Robertson's 41,113 shares of Common Stock are now reported as 0 following the merger.
• Stock options with an exercise price less than $1.75 per share were accelerated and treated like other shares in the tender offer.
• Stock options with an exercise price equal to or greater than $1.75 per share, which were unexercised, were canceled at the effective time of the merger.
• Former holders of canceled options are eligible to receive a cash retention bonus, subject to the achievement of certain net sales milestones, under a retention plan approved by the Issuer's Board of Directors' compensation committee.
• Ms. Robertson's stock options, with exercise prices ranging from $5.29 to $23.30, were all canceled, resulting in 0 beneficial ownership of these derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, which is generally a positive outcome for shareholders receiving consideration. While the reporting person's direct ownership is eliminated, the deal structure includes potential future value through CVRs and retention bonuses for employees, indicating a structured and complete transaction.

Positives

• The merger with Bausch Health Americas, Inc. was successfully completed, providing DURECT shareholders with immediate cash consideration.
• Shareholders also received contingent value rights (CVRs), offering potential future payments up to $350,000,000 based on milestone achievements.
• A retention plan was established for option holders whose options were canceled, providing eligibility for cash bonuses tied to net sales milestones.

Negatives

• The reporting person's direct beneficial ownership of DURECT common stock and stock options was reduced to zero following the merger.
• Stock options with exercise prices equal to or greater than the cash consideration of $1.75 per share were canceled, meaning they did not yield immediate value from the tender offer.

Risks

• The value of the contingent value rights (CVRs) is dependent on the achievement of specified milestones, which are not guaranteed.
• The eligibility for and amount of cash retention bonuses for former option holders are subject to the achievement of certain net sales milestones, introducing uncertainty.

Future Outlook

The future outlook for former DURECT shareholders includes potential additional cash payments from contingent value rights, which are tied to the achievement of specified milestones. For former option holders whose options were canceled, future cash retention bonuses are contingent on the achievement of certain net sales milestones.

Industry Context

This filing reflects the common outcome of an acquisition in the biotechnology or pharmaceutical industry, where a larger entity (Bausch Health) acquires a smaller company (DURECT). The use of contingent value rights (CVRs) is a frequent mechanism in such deals to bridge valuation gaps and provide upside potential tied to the acquired company's pipeline or future performance, particularly in drug development where outcomes are uncertain. The treatment of employee stock options, including acceleration for in-the-money options and retention plans for out-of-the-money options, is also standard practice to ensure continuity and incentivize key personnel post-acquisition.

Comparison to Industry Standards

• The acquisition structure, combining an upfront cash payment with contingent value rights (CVRs), aligns with common practices in the biotech and pharmaceutical sectors for M&A, such as the acquisition of Arena Pharmaceuticals by Pfizer or Acceleron Pharma by Merck, where CVRs are used to account for pipeline assets with uncertain future value.
• The $1.75 per share cash consideration, while specific to DURECT, would be evaluated against the company's pre-announcement trading price and analyst price targets, similar to how other acquisitions are assessed.
• The aggregate potential milestone payments of up to $350,000,000 via CVRs represent a significant portion of the deal's potential value, comparable to other biotech acquisitions where contingent payments can constitute a substantial part of the total consideration.
• The treatment of stock options, including acceleration for in-the-money options and cancellation with retention bonuses for out-of-the-money options, is a standard approach to manage employee equity incentives during a change of control, seen in numerous public company mergers.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $1.75 per share in cash and one non-tradeable contingent value right per share, converting their equity into cash and a future contingent claim.
• Employees (Option Holders): Those with in-the-money options saw accelerated vesting, while those with out-of-the-money options became eligible for cash retention bonuses tied to future performance, impacting their compensation and retention.
• Company (DURECT): Ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Bausch Health Americas, Inc.

Next Steps

• Achievement of specified milestones for the contingent value rights to trigger additional payments to former shareholders.
• Achievement of certain net sales milestones for former option holders to receive cash retention bonuses.

Key Dates

Recommendation

The company has been acquired and is no longer independently traded. For former shareholders, the cash portion of the consideration has been received. The remaining value is tied to the non-tradeable contingent value rights (CVRs). Therefore, the appropriate action is to 'hold' the CVRs and await the outcome of the specified milestones, as there is no public stock to actively buy or sell.

Keywords

DURECT, DRRX, Bausch Health, Merger, Tender Offer, Form 4, Beneficial Ownership, Stock Options, Contingent Value Rights, CVR, Corporate Governance